Printer Friendly

Tamoxifen Therapy Should Last 5 Years.

The much-criticized drug tamoxifen -- a synthetic hormone widely prescribed to prevent recurrences of breast cancer -- should be taken for 5 years after early-stage cancers are removed and should then be stopped, two new studies show.

Tamoxifen has been engulfed in controversy ever since several major studies detected a steep increase in the incidence of uterine cancer among women taking the drug.

Now, a Swedish study of 3887 women indicates that those who took tamoxifen for 5 years had fewer recurrences of breast cancer than women who took the drug for just 2 years. And a U.S. study of 2818 women found that the benefits of 5 years' worth of tamoxifen therapy persisted for 5 years but that there was no additional advantage of a longer course of treatment or any likelihood that a longer course would be worth the accompanying risk of uterine cancer.

-- Science News, 11/23/97
COPYRIGHT 1997 Association of Labor Assistants & Childbirth Educators
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1997, Gale Group. All rights reserved. Gale Group is a Thomson Corporation Company.

Article Details
Printer friendly Cite/link Email Feedback
Title Annotation:breast cancer therapy
Publication:Special Delivery
Geographic Code:1USA
Date:Mar 22, 1997
Previous Article:Estrogen and Breast Cancer.
Next Article:Abortion and Breast Cancer.

Related Articles
Beating breast cancer: researchers are looking beyond conventional surgeries and chemotherapy.
Blocking breast cancer: do faulty estrogen receptors make a meaner, tougher tumor?
Tamoxifen quandary; promising cancer drug may hide a troubling dark side.
Tamoxifen trial begins amid new concerns.
Studies spark new tamoxifen controversy.
Tamoxifen therapy should last 5 years.
Tamoxifen may not prevent breast cancer.
Tamoxifen clears hurdle to preventive use.
Protective progeny: peptide treats and prevents breast cancer.

Terms of use | Privacy policy | Copyright © 2020 Farlex, Inc. | Feedback | For webmasters